Effects of pravastatin and cholestyramine on circulating levels of parathyroid hormone and vitamin D metabolites.
The subjects were 40 hypercholesterolemic patients (mean age, 58 years) receiving a low-fat diet and randomly assigned to treatment with placebo for eight weeks or 40 or 80 mg of pravastatin, 24 gm of cholestyramine, or 40 mg of pravastatin plus 24 gm of cholestyramine daily for 24 weeks. After eight weeks of active treatment, levels of total and low-density lipoprotein cholesterol were significantly reduced and the decline was maintained for the remaining 16 weeks. Parathyroid hormone levels and levels of the vitamin D metabolites 1,25(OH)2D3 and 25(OH)D3 did not change during treatment. The results indicate that 24 weeks of treatment with pravastatin and cholestyramine does not affect calcium metabolism.
Ismail
F
F
University of Nevada-Reno School of Medicine.
Corder
C N
CN
Epstein
S
S
Barbi
G
G
Thomas
S
S
D002112:Calcifediol / Q000097:blood*; D002117:Calcitriol / Q000097:blood*; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D002792:Cholestyramine Resin / Q000494:pharmacology*; D004311:Double-Blind Method; D005260:Female; D006538:Heptanoic Acids / Q000494:pharmacology*; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000494:pharmacology*; D010281:Parathyroid Hormone / Q000097:blood*; D017035:Pravastatin; D014280:Triglycerides / Q000097:blood
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D006538:Heptanoic Acids; D009281:Naphthalenes; D010281:Parathyroid Hormone; D014280:Triglycerides; D002792:Cholestyramine Resin; D002784:Cholesterol; D002117:Calcitriol; D017035:Pravastatin; D002112:Calcifediol